Procedures & Techniques of PCI. 2021 ACC/AHA/SCAI guidelines.A discussion on Vascular access, stent types, Thrombectomy, CTO PCI, ISR, SVG - PCI, Hemodynamic Support for #PCI and many such topics. We have been discussing the 2021 #coronary revascularization guidelines given by #ACC. This is the 6th and the last video in this series. in this video w…

Revascularization in special situations - #pregnancy, old age, chronic kidney disease, cardiac allograft; revascularization to prevent ventricular tachycardia. Here is a discussion from 2021 ACC/AHA/SCAI GUIDELINES on Myocardial Revascularization. What to do in case of pregnancy? What to do in patients with #CKD? What to do in patients with old age…

ANTIPLATELET THERAPY BEFORE / DURING & AFTER PCI and CABG - 2021 ACC/AHA/SCAI GUIDELINES.A lot has changed in the field of Antiplatelet and antithrombotic therapy in patients undergoing #PCI or CABG. New evidence from trials like TWILIGHT trial, STOPDAPT trial, GLASSY & GLOBAL LEADER trial has made us reconsider what is optimal Antiplatelet Therapy…

TOMAHAWK trial or Angiography after Out-of-Hospital Cardiac Arrest without ST-Segment Elevation trial was recently published in #NEJM New England journal of Medicine and presented at the European Society of Cardiology Virtual Congress in 2021. It tested the strategy of immediate coronary angiography vs delayed or selective coronary angiography in p…

PARADISE MI Trial. ARNI in Acute Myocardial Infarction. NEJM 2021/ ACC 2021

Revascularization in stable CAD. ACC/AHA/SCAI guidelines 2021. Revascularization in stable CAD (coronary artery disease) had been a matter of debate in the field of Interventional Cardiology and cardiac surgery. What to do in patients with single vessel disease? What to do in patients with triple vessel disease?What to do in patients with Diabetes?…

Revascularization in NSTE- ACS (Non ST segment elevation acute coronary syndrome). 2021 ACC/AHA/STS/SCAI guidelines for myocardial revascularization -2. A discussion on every old and new concept in 2021 guidelines for myocardial revascularization. This was a huge 100+ page document, so breaking it down for easier discussion into multiple parts. Thi…

Revascularization in STEMI. 2021 ACC/AHA/STS/SCAI guidelines for myocardial revascularization -I. A discussion on every old and new concept in 2021 guidelines for myocardial revascularization. This was a huge 100+ page document, so breaking it down for easier discussion into multiple parts. This is first of many videos about to come on this documen…

EMPULSE Trial. EMPAGLIFLOZIN in Acute Heart Failure.EMPULSE TRIAL. EMPAGLIFLOZIN in patients with acute decompensated heart failure. #heart #cad #heartfailure #aha#cardioed #cardio #cardiologist #cardiologia #cardiologie #cardiovascular

Fractional Flow Reserve or FFR. #FFR. Fractional Flow Reserve is useful for assessment and management of intermediate coronary lesions, left main interventions, multivessel disease and stable CAD. #FractionalFlowReserve. Here is a discussion on applications of Fractional Flow Reserve OR FFR in Interventional Cardiology and the various trials suppor…

CHIEF HF Trial was recently presented at the AHA 2021 meeting. It tested an #SGLT2Inhibitor #CANAGLIFLOZIN in #HEARTFAILURE. CHIEF HF Trial or CANAGLIFLOZIN in HEART FAILURE which was recently presented at AHA 2021 is yet to be published. If you were searching about CHIEF HF Trial or role of CANAGLIFLOZIN in HEART FAILURE you can find it in this vi…

RAPID CABG Trial was recently presented at the AHA 2021. It tested the strategy of EARLY CABG AFTER TICAGRELOR vs delayed CABG after Ticagrelor administration.

CTCR - MVS Trial. Tricuspid valve repair in patients undergoing Mitral Valve surgery. AHA 2021. NEJM 2021.

REVERSE- IT Trial. Bentracimab for ticagrelor reversal. AHA 2021

AVATAR Trial. Aortic valve replacement in Asymptomatic Severe Aortic Stenosis. AHA 2021.

How to manage patients with stable coronary artery disease. First part of the discussion - a look at all the contemporary data we have.

Best Antithrombotic Regimen after Watchman device? - JACC Interventions

In the latest edition of #JACC Interventions, this recently published study titled "Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population" compared the patients in United States undergoing PCI for stable #coronary artery disease (#CAD) with recently published #ISCHEMIA stud…

The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial (#ACTIVATIONtrial) tested the strategy the #PCI before #TAVR Vs #TAVR without #PCI in patients with significant #CAD without significant #angina. Unfortunately the trial was terminated because of slow enrollment. Yet, it shed light on importan…

#EMPEROR PRESERVED trial was recently published in #NEJM in 2021. It was also presented at #ESC2021. Heart Failure with Preserved Ejection Fraction (#HFpEF) is responsible of more than half of the cases of heart failure. It is a difficult to diagnose and difficult to treat condition. #Emplagliflozin and #dapagloflozin are 2 #SGLT2inhibitors have be…

#FAME3 trial was recently published in #NEJM. Patients with three-vessel coronary artery disease have been found to have better outcomes with coronary-artery bypass grafting (#CABG) than with percutaneous coronary intervention (#PCI), but studies in which PCI is guided by measurement of fractional flow reserve (#FFR) have been lacking. The current …

#DeviceRelatedThrombosis after #LeftAtrialAppendageOcclusion is a problem which negates the very advantages of left atrial appendage occlusion. It increases the ischemic risk. The #LAAODRTregistry was a case control study of device related thrombosis in patients who received any of the left atrial appendage occlusion device like Watchman or ACP/Amu…

#Abelacimab for #VenousThromboembolism prevention after #TotalKneeReplacement, published in July 2021 edition of #NEJM. #Abelacimab is #MonoclonalAntibody against #Factor XI, a key component of #intrinsicCoagulationPathway. It has been used in prevention of Venous Thromboembolism after Total Knee Replacement and compared to #Enoxaparin. In this stu…

#ADAPTABLE trial was recently published in NEJM 2021 and it was also presented at ACC 2021 conference. It compared #HighDoseAspirin and #LowDoseAspirin in patients receiving it for secondary prevention. Follow Cardio-Ed for more such content. We discuss Recent advances, recent guidelines and recent articles in cardiology as well as core concepts in…

REHAB - HF trial was recently published in New England journal of medicine (NEJM) 2021 (July). It was also presented at the American College of Cardiology Virtual Annual Scientific Session (ACC 2021). The REHAB -HF trial tested the strategy of tailored rehabilitation program in older patients with acute heart failure. Acute heart failure in older p…

Role of omecamtiv mecarbil in heart failure with reduced ejection fraction (HFrEF) was published in GALACTIC- HF trial (NEJM 2021). Recently, in JACC the effect of ejection fraction on response to Omecamtiv mecarbil in patients enrolled in GALACTIC-HF trial was published. In this presentation I have discussed both these studies together. Omecamtiv …

In stent restenosis is common after POBA. in the era of DES also, it is responsible for 10% of all PCI. In this podcast i have discussed about definition of ISR (in stent restenosis), classification of ISR (in stent restenosis), risk factors of ISR (in stent restenosis), investigations of ISR (in stent restenosis), management of ISR (in stent reste…

Past, present and future of therapeutic hypothermia.Targeted temperature management (TTM) or Therapeutic hypothermia is recommended for patients after cardiac arrest, but the supporting evidence is of low certainty.TTM-2 trial was recently published in NEJM (June 2021).The TTM-2 trial tried to answer the question if Therapeutic hypothermia is any b…

Heart Failure with Preserved Ejection Fraction (HFpEF) is responsible of more than half of the cases of heart failure. It is a difficult to diagnose and difficult to treat condition. In this lecture i have summarized the available and upcoming drugs and other treatment modalities and evidence supporting each decision we make in HFpEF management. Wh…

FLOWER- MI trial was published in NEJM May 2021.The trial tested the strategy of FFR guided complete revascularization in STEMI and compared it to the angiography guided complete revascularization. I have discussed the trial in the podcast.Par Cardio-Ed

The LAAOS III was published in June 2021. The trial tested that if, on a background of anticoagulation, surgical left atrial appendage occlusion during cardiac surgery was beneficial or not. Do watch/ listen.Par Cardio-Ed

SGLT2 inhibitors are the new drugs which have been approved for heart failure with reduced ejection fraction (HFrEF). After the landmark EMPA-REG_OUTCOME, DECLARE TIMI 58, EMPEROR REDUCED and DAPA HF trials, empagliflozin and dapagliflozin have found a place in the management of HFrEF or heart failure. Lets discover what makes them special drugs in…

COVID-19 Vaccine Associated Thrombosis - What a medical practitioner should know? We have been listening about AstraZeneca vaccine associated thrombosis a lot. However, not much is known about this entity. I have tried to discuss Vaccine Associated Thrombosis in detail in this lecture. Do listen.Par Cardio-Ed

How to give anticoagulation in COVID-19 patients?How to choose the right patient, and right drug?How long to continue with anticoagulation in COVID19?I try to answer these questions. The presentation is not based on anecdotes/ experience. There arent any trials i am discussing here. Discussion strictly confined to International guidelines only.…